Cargando…

Patient perspectives on fluticasone–vilanterol versus other corticosteroid combination products for the treatment of asthma

OBJECTIVE: Fluticasone furoate (FF), an inhaled corticosteroid (ICS), and vilanterol (VI), a long-acting beta(2) receptor agonist (LABA), is a new combination used in an Ellipta(®) device. This article compares FF–VI to other ICS–LABA combinations available, particularly emphasizing product selectio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bollmeier, Suzanne G, Prosser, Theresa R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874727/ https://www.ncbi.nlm.nih.gov/pubmed/27257375 http://dx.doi.org/10.2147/PPA.S83946

Ejemplares similares

Fluticasone-formoterol: a systematic review of its potential role in the treatment of asthma
por: Prosser, Theresa R, et al.
Publicado: (2015)

New combination treatments in the management of asthma: focus on fluticasone/vilanterol
por: Tan, Laren D, et al.
Publicado: (2014)

Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma
por: O’Byrne, Paul M., et al.
Publicado: (2014)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
por: Day, Nicola C., et al.
Publicado: (2020)

Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthma–mixed treatment comparisons of clinical efficacy
por: Svedsater, Henrik, et al.
Publicado: (2016)

Efficacy and Safety of Fluticasone Furoate/Vilanterol Compared With Fluticasone Propionate/Salmeterol Combination in Adult and Adolescent Patients With Persistent Asthma: A Randomized Trial
por: Woodcock, Ashley, et al.
Publicado: (2013)

Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination
por: Oliver, A, et al.
Publicado: (2013)

Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone
por: Bateman, Eric D, et al.
Publicado: (2014)

Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial
por: Singh, Dave, et al.
Publicado: (2015)

Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy
por: Albertson, Timothy E, et al.
Publicado: (2016)

Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial
por: Furuhashi, Kazuki, et al.
Publicado: (2019)

A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD
por: Bhatt, Surya P, et al.
Publicado: (2017)

Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol
por: Molino, Antonio, et al.
Publicado: (2018)

Pharmacodynamics and Pharmacokinetics of Fluticasone Furoate/Vilanterol in Healthy Chinese Subjects
por: Chen, Xia, et al.
Publicado: (2015)

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
por: Bremner, Peter R., et al.
Publicado: (2018)

Patients with Asthma Prescribed Once-Daily Fluticasone Furoate/Vilanterol or Twice-Daily Fluticasone Propionate/Salmeterol as Maintenance Treatment: Analysis from a Claims Database
por: Atsuta, Ryo, et al.
Publicado: (2018)

Cost–consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma
por: Vallejo-Aparicio, Laura Amanda, et al.
Publicado: (2019)

Effect of once-daily fluticasone furoate/vilanterol versus vilanterol alone on bone mineral density in patients with COPD: a randomized, controlled trial
por: Maltais, Francois, et al.
Publicado: (2020)

Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD
por: Caramori, Gaetano, et al.
Publicado: (2014)

Treatment Patterns of New Users of Fluticasone Furoate/Vilanterol in Asthma and COPD in UK Primary Care: Retrospective Cohort Study
por: Dedman, Daniel, et al.
Publicado: (2019)

Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US
por: Bogart, Michael, et al.
Publicado: (2023)

Successful Treatment of Allergic Bronchopulmonary Aspergillosis Using a Combination of Inhaled Fluticasone Furoate/Vilanterol and Oral Voriconazole
por: Nishimatsu, Kanako, et al.
Publicado: (2020)

Randomised trial of once-daily vilanterol in children with asthma on inhaled corticosteroid therapy
por: Oliver, Amanda J., et al.
Publicado: (2016)

Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers
Publicado: (2016)

Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers
por: Brealey, Noushin, et al.
Publicado: (2015)

Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk
por: Covelli, Henry, et al.
Publicado: (2015)

Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial
por: Bardsley, George, et al.
Publicado: (2018)

Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences
por: Svedsater, Henrik, et al.
Publicado: (2018)

Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation
por: Hamouda, Mohamed, et al.
Publicado: (2023)

Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β(2) agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial
por: Busse, William W, et al.
Publicado: (2013)

A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects
por: Kempsford, Rodger, et al.
Publicado: (2014)

Cost-Effectiveness of Umeclidinium/Vilanterol versus Salmeterol/Fluticasone in Elderly Patients with Chronic Obstructive Pulmonary Diseases in China
por: Lan, Ying, et al.
Publicado: (2022)

Real-life effectiveness of fluticasone furoate/vilanterol after switching from fluticasone/salmeterol or budesonide/formoterol therapy in patients with symptomatic asthma: Relvar Ellipta for Real Asthma Control Study (RERACS study)
por: Shimizu, Yasuo, et al.
Publicado: (2020)

Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacy
por: Stynes, Gillian, et al.
Publicado: (2015)

Assessment of Medication Regimen Complexity of COPD Regimens in Individuals Visiting Community Pharmacies
por: Prosser, Theresa R, et al.
Publicado: (2023)

Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy
por: Lal, Chitra, et al.
Publicado: (2016)

Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease
por: Siederer, Sarah, et al.
Publicado: (2015)

A Rare Presentation of Drug-induced Liver Injury with Fluticasone and Vilanterol Inhaler Use
por: Rishi, Mohit, et al.
Publicado: (2019)

Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
por: Ismaila, Afisi S., et al.
Publicado: (2022)

Fluticasone furoate/vilanterol 92/22 µg once a day: a 12-month study on outcomes in mild to moderate asthma
por: Dal Negro, Roberto W., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_78hdre3oin55ubsc0aiqbrck1s